| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/17/2023 | 435.71% | Alliance Global Partners | → $7.5 | Initiates Coverage On | → Buy |
| 01/07/2022 | 400% | Maxim Group | → $7 | Initiates Coverage On | → Buy |
What is the target price for NeuroSense Therapeutics (NRSN)?
The latest price target for NeuroSense Therapeutics (NASDAQ: NRSN) was reported by Alliance Global Partners on July 17, 2023. The analyst firm set a price target for $7.50 expecting NRSN to rise to within 12 months (a possible 435.71% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroSense Therapeutics (NRSN)?
The latest analyst rating for NeuroSense Therapeutics (NASDAQ: NRSN) was provided by Alliance Global Partners, and NeuroSense Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for NeuroSense Therapeutics (NRSN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroSense Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroSense Therapeutics was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.
Is the Analyst Rating NeuroSense Therapeutics (NRSN) correct?
While ratings are subjective and will change, the latest NeuroSense Therapeutics (NRSN) rating was a initiated with a price target of $0.00 to $7.50. The current price NeuroSense Therapeutics (NRSN) is trading at is $1.40, which is within the analyst's predicted range.